Filtered By:
Specialty: Pharmaceuticals
Condition: Bleeding
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 53 results found since Jan 2013.
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Aspirin green light for brain bleed stroke patients, study finds
People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major clinical trial has found. Researchers say the findings are reassuring for the thousands of people who take the medicines to reduce their risk of heart attack and another common type of stroke caused by blood clots in the brain.
Source: World Pharma News - May 23, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
Data from Phase 3 ARISTOTLE trial pre-specified subanalysis published in the European Heart Journal
PRINCETON, N.J. & NEW YORK--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) today announced results of a... Biopharmaceuticals, CardiologyBristol-Myers Squibb, Pfizer, Eliquis, apixaban, atrial fibrillation, stroke
Source: HSMN NewsFeed - February 21, 2014 Category: Pharmaceuticals Source Type: news
Women: Don't Use Aspirin For Routine Prevention Of Heart Attacks, Stroke, And Cancer
Although once widely recommended, aspirin for the prevention of a first heart attack or stroke (primary prevention) has lost favor in recent years, as the large number of bleeding complications appeared to offset the reduction in cardiovascular events. But at the same time evidence has emerged demonstrating the long-term effect of aspirin in preventing colorectal cancer, leading some to think that the risk-to-benefit equation for aspirin should be reconsidered.
Source: Forbes.com Healthcare News - December 5, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
Bayer ’s Xarelto® significantly lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or peripheral artery disease by 24% (for specialized target groups only)
Importantly, rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin 100 mg once daily showed an unprecedented 42% relative risk reduction in stroke and 22% in cardiovascular death compared with aspirin 100 mg once daily alone / Bleeding rates were low, and while major bleeding was increased, notably there was no significant increase in intracranial or fatal bleeding / This combination regimen demonstrated a substantial improvement in net clinical benefit of 20%
Source: Bayer Company News - August 27, 2017 Category: Pharmaceuticals Source Type: news
XANTUS programme confirms low bleeding and low stroke rate with Xarelto ® in 11,121 prospectively investigated patients with atrial fibrillation
Results from an analysis of Bayer's XANTUS programme were recently published in the Journal of the American College of Cardiology (JACC)(1). The data confirm the safety profile of the oral Factor Xa inhibitor Xarelto® (rivaroxaban) in routine clinical practice. The analysis highlighted low bleeding and low stroke rates in patients with atrial fibrillation (AF) treated with Xarelto, as well as low rates of treatment discontinuation.
Source: World Pharma News - July 10, 2018 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
ASA: Intensive BP Control Lowers Bleeding Risk in Stroke Patients
TUESDAY, Feb. 12, 2019 -- Stroke patients who receive intensive blood pressure lowering are less likely to suffer brain bleeds when treated with clot-busting therapies, according to a study published online Feb. 7 in The Lancet to coincide with the...
Source: Drugs.com - Pharma News - February 12, 2019 Category: Pharmaceuticals Source Type: news
ACC: Catheter Ablation Does Not Cut Mortality, Stroke in A-Fib
WEDNESDAY, March 20, 2019 -- For patients with atrial fibrillation (AF), catheter ablation does not significantly reduce the risk for death, disabling stroke, serious bleeding, or cardiac arrest, but it does improve quality of life versus medical...
Source: Drugs.com - Pharma News - March 20, 2019 Category: Pharmaceuticals Source Type: news
Abbott Announces First-of-Its-Kind Trial to Assess New Therapy Option for People at Risk of Stroke
- The CATALYST trial will examine Abbott's Amplatzer ™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation
Source: Abbott.com - February 3, 2020 Category: Pharmaceuticals Source Type: news
ASA: Less Bleeding Seen With Tenecteplase for Ischemic Stroke
FRIDAY, Feb. 4, 2022 -- For patients with ischemic stroke, use of tenecteplase (TNK) for thrombolysis is associated with a lower rate of symptomatic intracranial hemorrhage (sICH) than alteplase (ALT), according to a study presented at the American...
Source: Drugs.com - Pharma News - February 4, 2022 Category: Pharmaceuticals Source Type: news
Brain Bleeds Up in Patients With COVID-19 Treated for Ischemic Stroke
THURSDAY, Nov. 10, 2022 -- Patients with acute ischemic stroke who also have COVID-19 have higher rates of intracranial bleeding complications and worse clinical outcomes following revascularization treatment than similar patients without COVID-19,...
Source: Drugs.com - Pharma News - November 10, 2022 Category: Pharmaceuticals Source Type: news
Incidence of Ischemic Stroke in Seniors Not Reduced by Low-Dose Aspirin
FRIDAY, July 28, 2023 -- For healthy older adults, low-dose aspirin does not reduce the risk for ischemic stroke but is associated with an increased risk for intracranial bleeding, according to a study published online July 26 in JAMA Network...
Source: Drugs.com - Pharma News - July 28, 2023 Category: Pharmaceuticals Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
